Delcath Adds Providence Cancer Center to Phase III Melanoma Trial
Posted on: Friday, 26 September 2008, 09:00 CDT
Delcath Systems, a medical technology company specializing in cancer treatment, has announced that the Robert Franz Cancer Research Center, a part of the Providence Cancer Center, located in Portland, Oregon, has joined Delcath's Phase III clinical trial for the treatment of inoperable metastatic melanoma in the liver using the company's percutaneous hepatic perfusion system.
This pivotal multi-center study for the isolated, high dose delivery of the anticancer agent melphalan is led by the National Cancer Institute. Providence, the 10th center to join this trial, will be able to provide this treatment option to a previously unreached patient population in the Pacific Northwest region of the US.
Delcath is announcing the expansion of this trial following Providence entering into a clinical research agreement with Delcath. Walter Urba, medical director of the Robert Franz Cancer Research Center and Earle Chiles Research Institute - a part of the Providence Cancer Center - will serve as the principal investigator of the study.
Richard Taney, president and CEO of Delcath, said: "The addition of Providence Cancer Center to this trial further propels Delcath towards its goal of completing enrollment in 2009. For decades, Dr Urba has been a leader in the research and implementation of melanoma treatments and he brings to this trial significant clinical and academic experience."
Source: Datamonitor
Related Articles
- UPDATE: FDA Approves Pralatrexate for Treatment of Peripheral T-Cell Lymphoma; Drug Discovered and Developed by SRI International, Memorial Sloan-Kettering Cancer Center, and Southern Research Institute
- FDA Approves Pralatrexate for Treatment of Peripheral T-Cell Lymphoma; Drug Discovered and Developed by SRI International, Memorial Sloan-Kettering Cancer Center, and Southern Research Institute
- Video: MADIT-CRT Trial Results Provide Clinical Evidence That Cardiac Resynchronization Therapy Significantly Slows Heart Failure Progression
- New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants
- Pioneering Cancer Center Introduces Advanced Varian RapidArc(TM) Treatments for Cancer Patients in Central Germany
- Providence Holy Cross Cancer Center Offers Advanced Image-Guided Radiotherapy Treatments Using New Technology From Varian Medical Systems
- Elekta and Warsaw Cancer Center Secure Advanced Cancer Treatments for Patients in Poland
- Southeast Nebraska Cancer Center Receives Major Research Funding
- Urbana Cancer Center Joins in Major Drug Trial
- H. Lee Moffitt Cancer Center and Genetronics Initiate Phase I Clinical Trial in Patients With Malignant Melanoma
 |
 |
User Comments (0)
RSS Feeds